|
|
| | Pioglitazone Basic information |
| Product Name: | Pioglitazone | | Synonyms: | 5-[[4-[2-(5-Ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione;Pioglitazone;5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}Methyl)-1,3-thiazolidine-2,4-dione hydrochloride;5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione | | CAS: | 105355-27-9 | | MF: | C19H20N2O3S | | MW: | 356.44 | | EINECS: | | | Product Categories: | | | Mol File: | 105355-27-9.mol |  |
| | Pioglitazone Chemical Properties |
| form | solid | | InChI | 1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23) | | InChIKey | HYAFETHFCAUJAY-UHFFFAOYSA-N | | SMILES | O=C(N1)C(SC1=O)CC(C=C2)=CC=C2OCCC(N=C3)=CC=C3CC |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral
Carc. 2 |
| | Pioglitazone Usage And Synthesis |
| Definition | ChEBI: Pioglitazone is a member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity. It has a role as an insulin-sensitizing drug, an EC 2.7.1.33 (pantothenate kinase) inhibitor, a xenobiotic, an EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor, a ferroptosis inhibitor, a cardioprotective agent, a PPARgamma agonist, an antidepressant, a geroprotector and a hypoglycemic agent. It is a member of thiazolidinediones, an aromatic ether and a member of pyridines. | | Clinical Use | Treatment of type 2 diabetes mellitus | | Metabolism | Pioglitazone undergoes extensive hepatic metabolism
by hydroxylation mainly via cytochrome P450 2C8
to form active and inactive metabolites. Three of the
six identified metabolites are active (M-II, M-III, and
M-IV). Following oral administration of radiolabelled
pioglitazone to man, recovered label was mainly in faeces
(55%) and a lesser amount in urine (45%). |
| | Pioglitazone Preparation Products And Raw materials |
|